Johnson & Johnson Seeks Emergency Use Authorization for Vaccine
On Thursday, Johnson & Johnson asked US regulators to approve emergency use authorization of its Covid-19 vaccine. If approved, it would be the first single-dose vaccine authorized to treat the virus.
Last Friday, Johnson & Johnson revealed that their one-shot Covid-19 vaccine is 66% effective at preventing moderate to severe Covid-19 symptoms and 85% effective against very serious symptoms. The J&J vaccine was less effective against the mutated South African version of the virus.
J&J says they can roll-out 100 million doses by the end of June, if they receive FDA approval.
Although less effective than the two-dose Pfizer and Moderna vaccines, J&J's single-dose vaccine could be much easier to roll-out and does not require the same sub-zero refrigeration, facilitating transportation and storage.
Photo Source: Pixabay